Drug intelligence / Profile preview

AdenoMax

Development stage: Preclinical
Lead developer: Vaccine Valley
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular, Subcutaneous

Overview

AdenoMax is an inactivated multivalent vaccine developed by Vaccine Valley to protect poultry, including broilers, layers, and breeders, against Inclusion Body Hepatitis (IBH) and Hydropericardium Hepatitis Syndrome (HHS). These conditions are caused by various serotypes of Fowl Adenovirus (FAdV). The vaccine is formulated with an oil adjuvant to enhance the immune response and provide broad protection against FAdV-associated diseases. It is currently in the preclinical stage of development and is designed to induce active immunity in poultry populations to prevent the significant economic losses associated with FAdV infections.

Brand names: AdenoMaxValleyVac AdenoMax
Other names: Adeno Max

Beyond the preview

Go deeper on AdenoMax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdenoMax.

Explore the full profile